

BC Cancer ST Program Updates for February 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - Do not** use the Copy Forward functionality to ensure that the updates apply.



- IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).


Please see this month's changes below.

Protocols: MYDARLD and MYDARLDF

Cycles/PowerPlans: All associated treatment Powerplans

Changes:

Removed **Clinical Decision Support** Note Under Pre-Chemo Metrics: *Daratumumab start should also be delayed when lenalidomide cycle is being delayed*



List of PowerPlans:

- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycle 2
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 3 to 6
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 7+
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLD Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycle 2
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 3 to 6
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 7+
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Cycle 1
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycle 2
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycles 3 to 6
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycles 7+
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLDF Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycle 2
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycles 3 to 6
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycles 7+
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose IV Cycle 1
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1

Versioning: Yes

Jira: CST-348427

Protocols: GOCXCPNP and GOCXCPNBP

Cycles/PowerPlans: ONCP GO GOCXCPNP and ONCP GO GOCXCPNBP

Changes:

In the Scheduling phase, updated: **Follow Up - Clinic - Oncology On Treatment** order - 3rd order sentence:

- Follow Up: 3 weeks, Last Cycle. Return in 3 weeks for Doctor and **GOCXBP** or **GOCXBP6** (to continue pembrolizumab), Physician Specialty: Medical Oncology, Tumor Group: Gynecology

Component	Status	Dose ...	Details
ONCP GO GOCXCPNP Cycle 1, Scheduling (Initiated Pending)			
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit			Within 2 Weeks, Cycle 1: Chair time 195 minutes; Nurse time 75 minutes, Chair Time: 165 minutes, Nurs... Day 1
<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment			Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input type="checkbox"/> Follow Up - Clinic - Nurse Telephone Line Care (Follo...			Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input type="checkbox"/> Go to Chemo Calendar to send next cycle to scheduling wait list			Follow Up: 3 weeks, Physician Specialty: Medical Oncology, Tumor Group: Gynecology
			Follow Up: 3 weeks, Last Cycle. Return in 3 weeks for Doctor and GOCXBP or GOCXBP6 (to continue pembrolizumab), Physician Specialty: Medical Oncology, Tumor Group: Gynecology

Component	Status	Dose ...	Details
ONCP GO GOCXCPNBP Cycle 2, Scheduling (Initiated Pending)			
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit			Within 2 Weeks, Cycle 1: Chair time 225 minutes, Chair Time: 225 minutes, Nurse Time: 60 minutes, ONCP GO GOCXCPNBP Day 1
<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment			Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input type="checkbox"/> Follow Up - Clinic - Nurse Telephone Line Care (Follo...			Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input type="checkbox"/> Go to Chemo Calendar to send next cycle to scheduling wait list			Follow Up: 3 weeks, Physician Specialty: Medical Oncology, Tumor Group: Gynecology
			Follow Up: 3 weeks, Last Cycle. Return in 3 weeks for Doctor and GOCXBP or GOCXBP6 (to continue pembrolizumab with or without bevacizumab), Physician Specialty: Medical Oncology...

Versioning: Yes

Jira: CST-349931

Protocols: GITREMDUR

Cycles/PowerPlans: ONCP GI GITREMDUR Cycle 1 and ONCP GI GITREMDUR Cycles 2+

Changes:

ONCP GI GITREMDUR Cycle 1:

- Renamed "Labs" phase to "Next Cycle Labs"
- Added an unselected Gamma Glutamyl Transferase under "If clinically indicated"

ONCP GI GITREMDUR Cycle 1 - Cycle 1 Next Cycle Labs Day 1 (Future Pending) *Est. 23-Jan-2026 08:00		
Component	Day 1	Future Pending
<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit		*Est. 23-Jan-2026 08:00...
<input checked="" type="checkbox"/> If clinically indicated:		Planned
<input checked="" type="checkbox"/> Alpha 1 Fetoprotein (AFP) Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit		

ONCP GI GITREMDUR Cycles 2+:

- Added an unselected Gamma Glutamyl Transferase under “If clinically indicated”

ONCP GI GITREMDUR Cycles 2+ - Cycle 2, Next Cycle Labs (Day 1) (Future Pending) *Est. 23-Jan-2026 08:00		
Component	Day 1	Future Pending
<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Output...) Blood, once, Order for future visit		*Est. 23-Jan-2026 08:00...
<input checked="" type="checkbox"/> If clinically indicated:		Planned
<input checked="" type="checkbox"/> Alpha 1 Fetoprotein (AFP) Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit		
<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit		

Versioning: Yes

Jira: CST-349466

Protocols: GUEP, GUBEP, GOEP, GOBEP

Cycles/PowerPlans: ONCP GO GOBEP, ONCP GO GOEP, ONCP GO GUBEP, ONCP GO GUEP

Changes:

In the Scheduling Phase, updated Clinical Decision Note to: If aprepitant is ordered, ensure patient takes aprepitant 80 mg PO daily for Days 2 and 3, and up to Day 7 if ordered

Component	Day 1 Future Pending *Est. 31-Dec-2025 08:00 PST - 21 Days	Day 2 Future Pending *Est. 01-Jan-2026 08:00 PST - 21 Days	Day 3 Future Pending *Est. 02-Jan-2026 08:00 PST - 21 Days	Day 4 Future Pending *Est. 03-Jan-2026 08:00 PST - 21 Days	Day 5 Future Pending *Est. 04-Jan-2026 08:00 PST - 21 Days
8 mg PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Days 1 to 5	Planned	Planned	Planned	Planned	Planned
8 mg PO, once oncology, drug form: tab, Use Patient S... Between 30 and 60 minutes prior to treatment. Days 1 to 5	Planned	Planned	Planned	Planned	Planned
125 mg PO, once oncology, drug form: cap, Use Patient Su... Between 30 and 60 minutes prior to treatment. Day 1	Planned				
If aprepitant is ordered, ensure patient takes aprepitant 80 mg PO daily for Days 2 and 3, and up to Day 7 if ordered	Planned				
100 mg IV, once oncology, drug form: inj Between 30 and 60 minutes prior to etoposide. Days 1 to 5	Planned				

- Added scheduling orders: Schedule BCC Teach - Subcutaneous Injection for all sites:

Component	Status	Dose	Details
Infusion Chemotherapy Visit	Within 2 Weeks, Cycle 1: Chair time 150 minutes; Nurse time 60 minutes; Chair Time: 120 minutes, Nurs...		Day 1
Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 120 minutes, Nurse Time: 45 minutes, ONCP GO GOEP		Day 2
Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 120 minutes, Nurse Time: 45 minutes, ONCP GO GOEP		Day 3
Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 120 minutes, Nurse Time: 45 minutes, ONCP GO GOEP		Day 4
Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 120 minutes, Nurse Time: 45 minutes, ONCP GO GOEP		Day 5
Follow Up - Clinic - Oncology On Treatment			Physician Specialty: Medical Oncology, Tumor Group: Gynecology
Schedule BCC Teach - Subcutaneous Injection (Sched...			BCC SU Task, Patient education and first injection, Cycle TBD Day TBD: schedule patient education and...

- Schedule BCC Teach - Subcutaneous Injection
- Schedule BCC PG Teach - Subcutaneous Injection
- Schedule BCC AB Teach - Subcutaneous Injection
- Schedule BCC SU Teach - Subcutaneous Injection
- Schedule RHS Teach - Subcutaneous Injection
- Schedule BCC VI Teach - Subcutaneous Injection
- Schedule qGH Teach - Subcutaneous Injection

Versioning: Yes

Jira: CST-350000

Protocols: GOCXCPNBP






Cycles/PowerPlans: ONCP GO GOCXCPNBP Pretreatment Plan and ONCP GO GOCXCPNBP

Changes:

ONCP GO GOCXCPNBP Pretreatment Plan:



- Added yellow note 'Baseline chest x-ray required if CT Chest not done'

- Re-sequenced XR Chest
- Added CARD Echo and EC Echocardiogram orders

ONCP GO GOCXCPNBP Pretreatment Plan, Diagnostics (Future Pending)	
<input type="checkbox"/>	 Baseline chest x-ray required if CT chest not done
<input type="checkbox"/>	 XR Chest
<input type="checkbox"/>	 If clinically indicated:
<input type="checkbox"/>	 Electrocardiogram 12 Lead
<input type="checkbox"/>	 CARD Echo

ONCP GO GOCXCPNBP

- Added Magnesium Level and Calcium Level

ONCP GO GOCXCPNBP - Cycle 1, Next Cycle Labs (Day 1) (Future Pending)	
<input type="checkbox"/>	 Magnesium Level Blood, once, Order for future visit
<input type="checkbox"/>	 Calcium Level Blood, once, Order for future visit

Versioning: Yes

Jira: CST-348179

Protocols: GIGAVFFOXZ and GIGAVCOXZ

Cycles/PowerPlans: All associated Regimens and Powerplans

Changes:

- Updated Regimen and Link to Protocol note to: Palliative Treatment of Metastatic or Locally Advanced Gastric or Gastroesophageal Junction (GEJ) or **Esophageal** Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab

ONCP GI GIGAVFFOXZ Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2) (Future Pending)			
			Component
			Link to Protocol: Palliative Treatment of Metastatic or Locally Advanced Gastric or Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab

Versioning: Yes

Jira: CST-351870

Protocols: BRAVEVEX

Cycles/PowerPlans: ONCP BR BRAVEVEX (PO)

Changes:

- In the Prescriptions Phase, updated yellow note “Cycle 1: max 30 days..” to “First dispense: maximum 30 days; subsequent dispenses: maximum 90 days”
- In the Next Cycle Labs Phase, updated yellow note “Prior to Cycle 2...” to “After first 4 weeks of treatment, then prior to each visit:”

ONCP BR BRAVEVEX (PO) - Cycle 1, Prescriptions (Future Pending) *Est. 20-Jan-2026 11:3			
			Link to Protocol: Therapy for Advanced Breast Cancer Using Everolimus and Exemestane
			Revised: 3 Mar 2025
			Pre-Chemo Metrics
			Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$ within 96 hours
			Platelet Count Greater Than or Equal to $75 \times 10^9/L$ within 96 hours
			Treatment Regimen
			First dispense: maximum 30 days; subsequent dispenses: maximum 90 days
			everolimus
			exemestane
ONCP BR BRAVEVEX (PO) - Cycle 1, Scheduling (Initiated Pending) 20-Jan-2026 11:36 PS			
			Follow Up - Clinic - Oncology On Treatment
ONCP BR BRAVEVEX (PO) - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 13-Feb			
			After first 4 weeks of treatment, then prior to each visit:
			CBC and Differential

Versioning: Yes

Jira: CST-352993

Protocols: LUAVNIV, LUAVNIV4, LUAVPCIPNI, LUAVPCPMB, LUAVPGPMB, LUAVPMB, LUAVPMB6, LUAVPPIPNI, LUAVPPMB, LUAVPMBF, LUAVPMBF6, LUSCDURPE, LUMMIPNI, LUMMIPNI3, LUAVATZ, LUAVATZ4

Cycles/PowerPlans: All Pretreatment Powerplans

Changes:

- In the Baseline Labs Phase, removed the C-Reactive Protein order and Albumin Level order

ONCP LU LUAVATZ Pretreatment Plan, Baseline Labs (Day 1) (Future Pending)		
		Component
		If clinically indicated:
<input type="checkbox"/>		Free T3 Level (Free T3 Level Outpatient) Blood, Thyroid Cancer – Thyrotoxicosis, once, Order for future visit
<input type="checkbox"/>		Free T4 Level (Free T4 Level Outpatient) Blood, Thyroid Cancer – Thyrotoxicosis, once, Order for future visit
<input type="checkbox"/>		Lipase Blood, once, Order for future visit
<input type="checkbox"/>		Glucose Random Blood, once, Order for future visit
<input type="checkbox"/>		Adrenocorticotrophic Hormone (ACTH) Level Blood, once, Order for future visit
<input type="checkbox"/>		Testosterone Level Blood, once, Order for future visit
<input type="checkbox"/>		Estradiol Level Blood, once, Order for future visit
<input type="checkbox"/>		Follicle Stimulating Hormone Blood, once, Order for future visit
<input type="checkbox"/>		Luteinizing Hormone Blood, once, Order for future visit
		For women of child bearing potential if pregnancy

Versioning: No

Jira: CST-352921

Protocols: GOCXBP6

Cycles/PowerPlans: ONCP GO GOCXBP6

Changes:

- Yellow CDS note added after “Pre-Chemo Metrics”: May proceed with treatment on Day 1 if:

ONCP GO GOCXBP6 - Cycle 1, Chemotherapy (Day 1, 22) (Future Pending) *Est. 21-Jan-2026 08:00 PST - 42 Days		
Component	Day 1	Day 22
	Future Pending	Future Pending
	*Est. 21-Jan-2026 08:00...	*Est. 11-Feb-2026 08:00...
	Actions ▾	Actions ▾
Link to Protocol: Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab		
Revised: 1Feb 2026		
Pre-Chemo Metrics		
May proceed with treatment on Day 1 if:		
Alanine Aminotransferase Less Than or Equal to 3 x ULN within 96 hours		

Versioning: Yes

Jira: CST-350488

Protocols: SAAVGS

Cycles/PowerPlans: ONCP SA SAAVGS (PO) and ONCP SA SAAVGS Pretreatment Plan

Changes:

ONCP SA SAAVGS (PO) PowerPlan:

Next Cycle Labs Phase:

- Add Random Glucose
- Remove Uric Acid
- If Clinically Indicated:
- Add Thyroid Stimulating Hormone
- Add Uric Acid
- Add Electrolyte Panel Outpatient (Na, K)
- Remove Potassium Level
- Add Magnesium Level
- Add Yellow Note "If laboratory urinalysis for protein is greater than or equal to 1 g/L or dipstick urinalysis shows 2+ or 3+ proteinuria, then a 24 hr urine for total protein must be done within 3 days prior to the next cycle"
- Add Protein Urine 24 Hour
- Add Yellow Note "'Collection Information Urine 24 Hour' and 'Creatinine Urine 24 Hour' are required tests for 24 hour urine tests"

- Add Collection Information Urine 24 Hour
- Add Creatinine Urine 24 Hour
- Add Linkage for the following components with Exactly 3
 - Protein Urine 24 Hour
 - Collection Information Urine 24 Hour
 - Creatinine Urine 24 Hour

ONCP SA SAAVGS (PO) - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 01-Mar-2026 13:40 f			Day 1
	Component		Future Pending
			*Est. 01-Mar-2026 13:...
			Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Glucose Random Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Urinalysis (macroscopic (dipstick)) Urine, once, Order for future visit		Planned
	<input checked="" type="checkbox"/> TSH prior to every other cycle (ie. 1, 3, 5, 7, 9, etc.) and if clinically indicated		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Thyroid Stimulating Hormone Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Thyroid Stimulating Hormone Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Protein Level (Total Protein Level) Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Uric Acid Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Phosphate Level Blood, once, Order for future visit		
	<input checked="" type="checkbox"/> If laboratory urinalysis for protein is greater than or equal to 1 g/L or dipstick urinalysis shows 2+ or 3+ proteinuria, then a 24 hr urine for total protein must be done within 3 days prior to the next cycle		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Protein Urine 24 Hour Urine, once, Order for future visit		
	<input checked="" type="checkbox"/> 'Collection Information Urine 24 Hour' and 'Creatinine Urine 24 Hour' are required tests for 24 hour urine tests		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Collection Information Urine 24 Hour Urine, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Urine 24 Hour Urine, once, Order for future visit		

Diagnostics Phase:

- Add Electrocardiogram 12 Lead

Component		Status
ONCP SA SAAVGS (PO) - Cycle 1, Diagnostics (Future Pending)		
If clinically indicated:		
<input type="checkbox"/>	NM MUGA	
<input type="checkbox"/>	CARD Echo	
<input type="checkbox"/>	Electrocardiogram 12 Lead	

ONCP SA SAAVGS Pretreatment Plan:

Baseline Labs Phase:

- Add Yellow Note "Revised: 1 Feb 2026"
- Add Magnesium Level (Preselected)
- Add Phosphate Level (Preselected)
- Add Calcium Level (Preselected)
- Add Random Glucose (Preselected)

Component		Day 1
		Future Pending
		*Est. 21-Jan-2026 08:00...
		Actions
Revised: 1 Feb 2026		
<input checked="" type="checkbox"/>	CBC and Differential	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Sodium and Potassium Panel (Electrolytes Panel Output...	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Magnesium Level	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Phosphate Level	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Calcium Level	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Creatinine and Estimated GFR	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Protein Level (Total Protein Level)	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Albumin Level	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Bilirubin Total	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Alkaline Phosphatase	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Gamma Glutamyl Transferase	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Alanine Aminotransferase	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Urinalysis Macroscopic (dipstick)	Planned
Urine, once, Order for future visit		
<input checked="" type="checkbox"/>	Thyroid Stimulating Hormone	Planned
Blood, once, Order for future visit		
<input checked="" type="checkbox"/>	Glucose Random	Planned
Blood, once, Order for future visit		

Diagnostics Phase:

- Add Electrocardiogram 12 lead

	Component	Status
ONCP SA SAAVGS Pretreatment Plan, Diagnostics (Future Pending)		
	If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> NM MUGA	
<input type="checkbox"/>	<input checked="" type="checkbox"/> CARD Echo	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Electrocardiogram 12 Lead	

Versioning: Yes

Jira: CST-351023

Protocols: CNAJZRT and CNELTZRT

Cycles/PowerPlans: ONCP CN CNAJZRT Adjuvant (PO), ONCP CN CNELTZRT Adjuvant (PO)

Changes:

- Under the Scheduling phase, addition of new, yellow Clinical Decision Support note: For patients on adjuvant temozolomide and treated with Tumour Treating Fields, select one of the options below:
- Addition of new, Follow Up - Clinic - Nurse Telephone Line Care order: As Per Special Instructions, Phone, Symptom and side effect assessment during Tumour Treating Fields treatment, Schedule nurse phone call monthly
- Addition of new, Follow Up - Clinic - Nurse Visit order: As Per Special Instructions, In Person/Clinic, Symptom and side effect assessment during Tumour Treating Fields treatment, Schedule nurse in-clinic visit monthly
- The Follow Up - Clinic - Nurse Telephone Line Care and Follow Up - Clinic - Nurse Visit orders are linked so only ONE order can be placed at a given time
- BCC PG, BCC AB, BCC SU, and BCC VI nursing visit types are also included for both follow up clinic orders

	Component	Status	Dose ...	Details
ONCP CN CNAJZRT Adjuvant (PO) - Cycle 1, Scheduling (Initiated Pending)				
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment			Follow Up: 4 weeks, Physician Specialty: Medical Oncology, Tumor Group: Neuro
	For patients on adjuvant temozolomide and treated with Tumour Treating Fields, select one of the options below:			
<input type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Nurse Telephone Line Care (Follo...			As Per Special Instructions, Phone, Symptom and side effect assessment during Tumour Treating Fields treatment, Schedule nurse phone call monthly
<input type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Nurse Visit (Follow Up - Clinic - B...			As Per Special Instructions, In Person/Clinic, Symptom and side effect assessment during Tumour Treating Fields treatment, Schedule nurse in-clinic visit monthly

Component	Status	Dose ...	Details
ONCP CN CNEIZRT Adjuvant (PO) - Cycle 1, Scheduling (Initiated Pending)			
<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment			Follow Up: 4 weeks, DUAL MODALITY, Physician Specialty: Medical Oncology, Tumor Group: Neuro
<input checked="" type="checkbox"/> For patients on adjuvant temozolomide and treated with Tumour Treating Fields, select one of the options below:			
<input type="checkbox"/> Follow Up - Clinic - Nurse Telephone Line Care (Follo...			As Per Special Instructions, Phone, Symptom and side effect assessment during Tumour Treating Fields treatment, Schedule nurse phone call monthly
<input checked="" type="checkbox"/> Follow Up - Clinic - Nurse Visit (Follow Up - Clinic - B...			As Per Special Instructions, In Person/Clinic, Symptom and side effect assessment during Tumour Treating Fields treatment, Schedule nurse in-clinic visit monthly

Versioning: No

Jira: CST-350761

Net New Protocols:

- ONC GU UGUVERD (PO)
- ONCP GU UGUVERD (PO) Cycle 1
- ONCP GU UGUVERD (PO) Cycles 2+
- ONC LU LUAJPMB6
- ONCP LU LUAJPMB6 Pretreatment Plan
- ONCP LU LUAJPMB6
- ONC LU LUAJPMB
- ONCP LU LUAJPMB Pretreatment Plan
- ONCP LU LUAJPMB
- ONC LY LYPOLARCHP Cyclophosphamide Hyperbilirubinemia Option
- ONC LY LYPOLARCHP Etoposide Cardiac Dysfunction Option
- ONC LY LYPOLARCHP DOXOrubicin Option
- ONCP LY LYPOLARCHP Pretreatment Plan
- ONCP LY LYPOLARCHP Cyclophosphamide Hyperbilirubinemia Option Cycle 1
- ONCP LY LYPOLARCHP Cyclophosphamide Hyperbilirubinemia Option Cycles 2 to 6
- ONCP LY LYPOLARCHP Etoposide Cardiac Dysfunction Option Cycle 1
- ONCP LY LYPOLARCHP Etoposide Cardiac Dysfunction Option Cycles 2 to 6
- ONCP LY LYPOLARCHP DOXOrubicin Option Cycle 1
- ONCP LY LYPOLARCHP DOXOrubicin Option Cycles 2 to 6
- ONC LU LUNAPPPMB CARBOplatin Option Neoadjuvant Phase
- ONC LU LUNAPPPMB CISplatin Option Neoadjuvant Phase
- ONC LU LUNAPPPMB Every 3 Week Option Adjuvant Phase
- ONC LU LUNAPPPMB Every 6 Week Option Adjuvant Phase
- ONCP LU LUNAPPPMB Pretreatment Plan
- ONCP LU LUNAPPPMB CARBOplatin Option Neoadjuvant Phase
- ONCP LU LUNAPPPMB CISplatin Option Neoadjuvant Phase
- ONCP LU LUNAPPPMB Every 3 Week Option Adjuvant Phase

- ONCP LU LUNAPPPMB Every 6 Week Option Adjuvant Phase
- ONC LU LUNAPGPMB CARBOplatin Option Neoadjuvant Phase
- ONC LU LUNAPGPMB CISplatin Option Neoadjuvant Phase
- ONC LU LUNAPGPMB Every 3 Week Option Adjuvant Phase
- ONC LU LUNAPGPMB Every 6 Week Option Adjuvant Phase
- ONCP LU LUNAPGPMB Pretreatment Plan
- ONCP LU LUNAPGPMB CARBOplatin Option Neoadjuvant Phase
- ONCP LU LUNAPGPMB CISplatin Option Neoadjuvant Phase
- ONCP LU LUNAPGPMB Every 3 Week Option Adjuvant Phase
- ONCP LU LUNAPGPMB Every 6 Week Option Adjuvant Phase

Jira: CST-350113, CST-350052, CST-350054, CST-350055, CST-350058, CST-350057

Jira Ticket #	CST-352993, CST-352921, CST-351870, CST-351023, CST-350488, CST-350113, CST-350058, CST-350057, CST-350055, CST-350054, CST-350052, CST-350000, CST-349931, CST-349466, CST-348427, CST-348179, CST-350761
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444